Overview

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Status:
Terminated
Trial end date:
2017-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
BMS-955176
Emtricitabine